Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)

Average per-patient trial costs across all therapeutic areas:

Phase I: $21,883

Phase II: $36,070

Phase IIIa: $47,523

Phase IIIb: $47,095

Phase IV: $17,042

Average cost per patient for a cardiovascular trial:

Phase II: $33,700

Phase IIIa: $21,750

Phase IIIb: $6,830

In oncology, the average per patient trial cost:

Phase II: $73,303

Phase IIIa: $57,207

Phase IIIb: $65,900

For central nervous system disorders:

Phase II: $28,197

Phase IIIa: $33,768

Phase IIIb: $41,824

For diabetes:

Phase II: $ 8,854

Phase IIIa: $12,667

Phase IIIb: $10,700

Anyone have any thoughts or data as to how this compares to cell therapy trials?

--Lee

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com